Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 50 percent increase over losses of $(0.60) per share from
Lexeo lost more money per share than experts expected, but the good news is their losses are getting smaller over time. When a company is losing less money than before, it hints they might be moving toward making a profit someday.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.